OpenAlex
PricingAboutJobs
Log inGet started
Work

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

HTML

Year: 2019
Type: article
Study design: Clinical Trial
Source: The Lancet Oncology
DOI: 10.1016/s1470-2045(19)30331-6
Authors: Georgina V Long, Robyn P M Saw, Serigne Lo, Omgo E Nieweg, Kerwin F Shannon, Maria Gonzalez, Alexander Guminski, Jenny H Lee, Hansol Lee, Peter M Ferguson, Robert V Rawson, James S Wilmott, John F Thompson, Richard F Kefford, Sydney Ch'ng, Jonathan R Stretch, Louise Emmett, Rony Kapoor, Helen Rizos, Andrew J Spillane, Richard A Scolyer, Alexander M Menzies
Institutions: The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia, Royal Prince Alfred Hospital, Macquarie University, St Vincent's Hospital Sydney
Language: English

Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: neoadjuvant therapy, dabrafenib, trametinib, BRAF V600 mutation, melanoma, stage III melanoma, pathological complete response, RECIST response, adjuvant therapy, tumor resection, BRAF inhibitor resistance, MAPK inhibition, BRAF wild-type melanoma, BRAF V600D
SDG: Good health and well-being

Open Access status: closed

Funder: Amgen
OpenAlex ID: W2947338182
FWCI: 6.425
Cites: 24
Cited by: 208
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security